Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, +30

Blood

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, +35

Journal of the National Comprehensive Cancer Network

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières, +21

Leukemia

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Joshua Brody, Judit Jørgensen, David Belada, +16

Blood

Cell TherapyTransplant-ineligible Relapsed/refractory DlbclTransplantation MedicineImmunologyR/r Dlbcl +17

Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data

Yasmin Karimi, Douglas W. Blayney, Allison W. Kurian, +4

JCO Clinical Cancer Informatics

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

Adam Zayac, Daniel J. Landsburg, Mitchell E. Hughes, +37

Blood Advances

ImmunologyPathologyImmunotherapyTumor BiologyMyeloid Neoplasia +14

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.

Lorenzo Falchi, Fritz Offner, David Belada, +10

Journal of Clinical Oncology

Clinical ImmunologyImmunodeficienciesImmunologyImmune RegulationPathology +22

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

Tycel Phillips, David A. Bond, Radihka Takiar, +14

Blood Advances

Untreated MclImmunologyPathologyImmunotherapyTumor Biology +14

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Julie M. Vose, Chan Y. Cheah, Michael Roost Clausen, +17

Blood

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Taylor Brooks, Emily C. Zabor, Yohana B. Bedelu, +39

Blood